You can buy or sell TYME and other stocks, options, ETFs, and crypto commission-free!
Tyme Technologies, Inc. operates as a clinical-stage biopharmaceutical company focused on development and commercialization of highly targeted cancer therapeutics with a broad range of oncology indications. Its clinical program, SM-88 is a novel combination therapy based on dysfunctional metyrosine derivatives and has shown complete or partial imaging responses in 15 different cancer subtypes, including solid tumors, sarcomas, gliomas and hematological malignancies, without demonstrating drug-related severe adverse events. Read More The company was founded on November 22, 2011 and is headquartered in New York, NY.
New York, New York
52 Week High
52 Week Low
DEADLINE MONDAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Tyme Technologies, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
LOS ANGELES, March 22, 2019 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Tyme Technologies, Inc.
Yahoo FinanceMar 21
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of TYME, UMC and BPI
NEW YORK, NY / ACCESSWIRE / March 21, 2019 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies.
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 in Tyme Technologies, Inc. to Contact the Firm
NEW YORK--(BUSINESS WIRE)--Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Tyme Technologies, Inc.
Expected Jun 13, Pre-Market